Biotechnology

Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in China

SUZHOU, China, Aug. 9, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company has completed the enrollment and dosing of 92 subjec...

2022-08-09 17:00 2261

Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-004

SAN DIEGO, SHANGHAI and HONG KONG, Aug. 9, 2022 /PRNewswire/ -- Inmagene Biopharmaceutical ("Inmagene ") and HUTCHMED (China) Limited ("HUTCHMED ") (Nasdaq/AIM:HCM; HKEX:13) announce today that the first participant, based inthe United States,...

2022-08-09 12:00 1718

BGI Ranks No. 1 among APAC and China Life Science Corporations for Seven Consecutive Years: 2022 Nature Index Annual Tables Revealed

SHENZHEN, China, Aug. 8, 2022 /PRNewswire/ -- BGI has topped the Asia Pacific andChina life science corporate institution ranking table for the seventh year running, released in the 2022 Nature Index Annual Tables. With a 19 percent increase in its adjusted share metric, BGI ranked eighth among g...

2022-08-08 22:00 2208

ImmVira's Brand New oHSV Product MVR-C5252 Targeting Malignant Glioma Obtained FDA's Orphan Drug Designation

SHENZHEN, China, Aug. 7, 2022 /PRNewswire/ -- On August 1, 2022, U.S. time, ImmVira's brand new oncolytic herpes simplex virus ("oHSV") product MVR-C5252 targeting Malignant Glioma has obtained Orphan Drug Designation ("ODD") from U.S. Food and Drug Administration ("FDA").

2022-08-08 08:30 1552

Epigenic Therapeutics Raises $20 Million in Series Angel and Pre-A Funding to Advance Next Generation Gene Editing Therapy

SHANGHAI, Aug. 6, 2022 /PRNewswire/ -- Epigenic Therapeutics Co., Ltd., a frontier biotechnology company dedicated to developing next generation gene editing therapy utilizing regulation of epigenetic genome for wide variety of diseases, today announced it has secured$20 million in Series Angel a...

2022-08-07 07:00 3301

United BioPharma's Study Reveals New Class of Monoclonal Antibody for Effective Relief of Urticaria Symptoms

New results demonstrate a newer class of anti-IgE antibody, UB-221, with superior neutralization, synthesis reduction, and durable relief in targeting allergic diseases  TAIPEI, Aug. 5, 2022 /PRNewswire/ -- United BioPharma (UBP) today announced their latest results featuring unprecedented and u...

2022-08-05 20:45 4832

Yiling's Lianhua Health Products Well-received: CICPE

SHIJIAZHUANG, China, Aug. 5, 2022 /PRNewswire/ -- As China's first national-level consumer expo and the largest such kind in theAsia-pacific region, the 2nd China International Consumer Products Expo (CICPE) attracted many audiences from different countries. And as the TOP 10 Chinese TCM Enterpr...

2022-08-05 15:54 4252

CGBio Signing a North America Out-license Contract on "Novosis rhBMP-2," a Bone Substitute with Orthofix, USA

* Embarking on a successful journey of exporting its home-grown product technology toNorth America, the largest market for bone substitutes * Enabling fast bone formation by applying bone morphogenetic protein (rhBMP-2) and next-generation synthetic carrier SEOUL, South Korea and LEWISVILLE, ...

2022-08-04 21:00 2383

RADIOPHARM ENTERS INTO STRATEGIC COLLABORATION WITH LANTHEUS AND ASSUMES PD-L1 LICENSING AGREEMENT FROM NANOMAB

* Radiopharm will shortly initiate a PD-L1 Phase 1 therapeutic study in Australia in patients with NSCLC * Radiopharm acquired from NanoMab, Ltd. worldwide rights to PD-L1 technology for therapeutic use, as well as to imaging rights inChina MELBOURNE, Australia, Aug. 3, 2022 /PRNewswire/ -- R...

2022-08-04 10:15 1569

ST Pharm Presents Phase 1 Clinical Trial Results of HIV Treatment Candidate at AIDS 2022

-   STP0404 is the only clinical safety proven HIV treatment candidate with a novel mechanism that can block HIV re-activation. -   STP0404 is expected to enter Phase 2a clinical trial in the US in 4Q 2022. SEOUL, South Korea, Aug. 3, 2022 /PRNewswire/ -- ST Pharm Co., Ltd. (237690:KOSDAQ) annou...

2022-08-03 20:00 1913

Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US

SUZHOU, China, Aug. 3, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company completed the enrollment of 121 patients for its pha...

2022-08-03 19:38 1513

Sanyou Biopharmaceuticals Closed the Series B+ Financing Round of Tens of Millions of RMB Led by Huatai Zijin

SHANGHAI, Aug. 2, 2022 /PRNewswire/ -- Sanyou Biopharmaceuticals Co., Ltd. announced that it has closed the Series B+ financing round of tens of millions of RMB. In this round of financing led by Zijin Hongyun Fund and Huatai Guoxin Fund under Huatai Zijin, Sanyou also received follow-on investme...

2022-08-03 08:00 1730

GenKOre develops hypercompact base editing system

DAEJEON, South Korea , Aug. 2, 2022 /PRNewswire/ -- GenKOre (homepage: www.genkore.com ), a biotech start-up in Korea, had a study on the development of hypercompact adenine base editors (ABEs) published on Nature Chemical Biology onAugust 2, 2022.

2022-08-02 22:44 2092

Gracell Biotechnologies to Report Second Quarter 2022 Financial on Monday, August 15, 2022

SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Aug. 2, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today a...

2022-08-02 21:00 1990

CARsgen Appoints Dr. Hua Jiang as Executive Director

SHANGHAI, Aug. 2, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces thatDr. Hua Jiang ("Dr. Jiang") has been appointed as Executive Direct...

2022-08-02 20:50 2154

"OpenDEL®3.0 - DRUG DISCOVERY PARTNER" webinar offered by HitGen and Endpoints News coming up on Thursday 4th August

CHENGDU, China, Aug. 1, 2022 /PRNewswire/ -- "OpenDEL®3.0 – DRUG DISCOVERY PARTNER" webinar will be jointly held by HitGen Inc. and Endpoints News on Thursday 4th August, to present you with a high-quality DEL product with all DEL information sharing and technical support. Dr. Guansai Liu, Execut...

2022-08-01 22:00 1957

Yunji's Technology-empowered Private Label SUYE Celebrates Its 12th Anniversary

HANGZHOU, China, Aug. 1, 2022 /PRNewswire/ -- Yunji Inc. ("Yunji" or the "Company") (NASDAQ: YJ), a leading membership-based social e-commerce platform, today announced the celebration of its private-label skin care brand SUYE's 12th anniversary. SUYE generated over21 million RMB sales of its hig...

2022-08-01 21:00 2704

GreenLight Biosciences and Samsung Biologics complete first commercial-scale engineering run for mRNA Covid-19 vaccine

* GreenLight's messenger RNA production process is transferable to large-scale equipment and CMO facilities * Technology transfer and scale-up from lab bench to Samsung's commercial facility was completed in seven months * GreenLight's mRNA synthesis reaction had a titer of 12g/L at a commer...

2022-08-01 21:00 2265

Gracell Biotechnologies Appoints Accomplished Clinical Leader Dr. Wendy Li as Chief Medical Officer

Dr. Li brings deep oncology clinical development, medical affairs and U.S. regulatory experience SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, Aug. 1, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical compa...

2022-08-01 20:00 1925

Eccogene Announces US IND Approval for THRβ agonist ECC4703

SHANGHAI, Aug. 1, 2022 /PRNewswire/ -- Eccogene announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to commence Phase I trial of its thyroid hormone receptor agonist ECC4703 in U.S. This study will evaluate the safety, tolerabilit...

2022-08-01 15:00 1542
1 ... 73747576777879 ... 129

Week's Top Stories